Famotidine 20/40 mg tabs — $0 with Membership

Related medications

Other medications associated with the same conditions in this catalog.

Also listed for GERD / Acid Reflux

• Esomeprazole
• Omeprazole
• Pantoprazole

About Famotidine 20/40 mg tabs

Famotidine, a widely trusted medication, provides effective relief from heartburn and acid reflux, helping countless individuals find comfort. At TheDrugClub, we're dedicated to making essential prescriptions like famotidine affordable and accessible. Our members enjoy incredible savings, ensuring you can manage your symptoms without financial stress, often at no co-pay.

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Famotidine 20/40 mg tabs is approved for (FDA label)

Famotidine tablets are indicated in adult and pediatric patients 40 kg and greater for the treatment of: • active duodenal ulcer (DU). • active gastric ulcer (GU). • symptomatic nonerosive gastroesophageal reflux disease (GERD). • erosive esophagitis due to GERD, diagnosed by biopsy. Famotidine tablets are indicated in adults for the: • treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine neoplasias). • reduction of the risk of duodenal ulcer recurrence. Famotidine is a histamine-2 (H 2 ) receptor antagonist indicated ( 1 ): In adult and pediatric patients 40 kg and greater for the treatment of: • active duodenal ulcer (DU). • active gastric ulcer. • symptomatic nonerosive gastroesophageal reflux disease (GERD).

Source: Read the full FDA label on DailyMed. Label effective date: September 9, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Famotidine 20/40 mg tabs (FDA label)

• Famotidine Tablets USP, 40 mg are White, round, film-coated tablets debossed with “12” on one side and “plain” on other side. Tablets: 40 mg ( 3 )

Source: FDA prescribing information (DailyMed). Set ID: 669fbd46-cae5-4477-884e-8eca893d2e05. SPL document ID: 5b129e06-e722-6e90-e063-6394a90a3944. Label effective date: September 9, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Famotidine 20/40 mg tabs (FDA label)

The most common adverse reactions are: headache, dizziness, constipation, and diarrhea. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Novadoz Pharmaceuticals LLC at 1-855-668-2369 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Trial Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Source: FDA prescribing information (DailyMed). Set ID: 669fbd46-cae5-4477-884e-8eca893d2e05. SPL document ID: 5b129e06-e722-6e90-e063-6394a90a3944. Label effective date: September 9, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Famotidine 20/40 mg tabs (FDA label)

Famotidine tablets are contraindicated in patients with a history of serious hypersensitivity reactions (e.g., anaphylaxis) to famotidine or other histamine-2 (H 2 ) receptor antagonists. History of serious hypersensitivity reactions (e.g., anaphylaxis) to famotidine or other H 2 receptor antagonists. ( 4 )

Source: FDA prescribing information (DailyMed). Set ID: 669fbd46-cae5-4477-884e-8eca893d2e05. SPL document ID: 5b129e06-e722-6e90-e063-6394a90a3944. Label effective date: September 9, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Famotidine 20/40 mg tabs (FDA label)

• Central Nervous System (CNS) Adverse Reactions : Elderly patients and patients with renal impairment at increased risk; reduce the dosage. ( 2.2 , 5.1 , 8.5 , 8.6 ) • GI Malignancy : Absence of GI symptoms does not preclude the presence of gastric malignancy; evaluate prior to initiating therapy. ( 5.2 ) 5.1 Central Nervous System Adverse Reactions Central nervous system (CNS) adverse reactions, including confusion, delirium, hallucinations, disorientation, agitation, seizures, and lethargy, have been reported in elderly patients and patients with moderate and severe renal impairment treated with famotidine. Since famotidine blood levels are higher in patients with renal impairment than in patients with normal renal function, dosage adjustments are recommended in patients with renal impairment [ see Dosage and Administration (2.2) , Clinical Pharmacology (12.3) ]. 5.2 Concurrent Gastric Malignancy In adults, symptomatic response to therapy with famotidine does not preclude the presence of gastric malignancy.

Source: FDA prescribing information (DailyMed). Set ID: 669fbd46-cae5-4477-884e-8eca893d2e05. SPL document ID: 5b129e06-e722-6e90-e063-6394a90a3944. Label effective date: September 9, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Famotidine 20/40 mg tabs (FDA label)

• Drugs Dependent on Gastric pH for Absorption : Systemic exposure of the concomitant drug may be significantly reduced leading to loss of efficacy. See full prescribing information for a list of interacting drugs. ( 7.1 ) • Tizanidine (CYP1A2) Substrate : Potential for substantial increases in blood concentrations of tizanidine resulting in hypotension, bradycardia or excessive drowsiness; avoid concomitant use, if possible. ( 7.2 ) 7.1 Drugs Dependent on Gastric pH for Absorption Famotidine can reduce the absorption of other drugs, due to its effect on reducing intragastric acidity, leading to loss of efficacy of the concomitant drug. Concomitant administration of famotidine with dasatinib, delavirdine mesylate, cefditoren, and fosamprenavir is not recommended.

Source: FDA prescribing information (DailyMed). Set ID: 669fbd46-cae5-4477-884e-8eca893d2e05. SPL document ID: 5b129e06-e722-6e90-e063-6394a90a3944. Label effective date: September 9, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.